

MARKET REPORT



Multiple Myeloma: Epidemiology Forecast to 2027

BioPortfolio
Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data



Multiple Myeloma: Epidemiology Forecast to 2027

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

We look forward to being of service to you.

If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.

Phone: +44 (0)7887 945155 or **Email:** pdb@bioportfolio.co.uk

Multiple Myeloma: Epidemiology Forecast to 2027

Multiple Myeloma: Epidemiology Forecast to 2027

Summary

Multiple myeloma (MM) (International Statistical Classification of Diseases and Related Health Problems, 10th Revision [ICD-10] code = C90.0) is a hematologic cancer that forms in a type of white blood cell called a plasma cell.

In 2017, the 8MM had 81,380 diagnosed incident cases of MM. This is expected to increase to 103,272 diagnosed incident cases by 2027, at an Annual Growth Rate (AGR) of 2.69%. The increase is driven by the aging population in the 8MM. In 2017, the 8MM had 353,890 diagnosed prevalent cases of MM. This is expected to increase to 555,243 diagnosed prevalent cases by 2027, at an AGR of 5.69%. The US had the highest number of diagnosed incident and diagnosed prevalent cases of MM. The development of more effective therapies, particularly for elderly patients, would improve survival and increase disease prevalence.

GlobalData's epidemiological forecast for the diagnosed incident cases of MM in the 8MM is supported by country-specific data for the age- and sex-specific diagnosed incidence of MM. Additionally, GlobalData adjusted the forecast to account for coding changes in MM diagnosis after 2014. The use of a consistent methodology across the 8MM to forecast the diagnosed incident cases and the diagnosed prevalent cases of MM allows for a meaningful comparison of the forecast incident cases and the forecast prevalent cases of MM in these markets.

Scope

The Multiple Myeloma Epidemiology Report provides an overview of the risk factors and global trends of multiple myeloma in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and China (Urban)). This report also includes a 10-year epidemiological forecast for the following segmentations -

- Diagnosed incident cases of MM
- Diagnosed prevalent cases of MM
- Diagnosed incident cases of MM by symptom status
- Diagnosed incident cases by stem cell transplantation (SCT) eligibility
- Diagnosed incident cases by high-risk cytogenetics (chromosomal abnormalities): t(4;14), t(14;16), t(14;20), and del(17/17p)
- Diagnosed incident cases by revised-international staging system (R-ISS) staging
- The multiple myeloma epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to buy

The Multiple Myeloma Epidemiology report will allow you to -

- Develop business strategies by understanding the trends shaping and driving the global multiple myeloma market.
- Quantify patient populations in the global multiple myeloma market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for multiple myeloma therapeutics in each of the markets covered.
- Understand magnitude of multiple myeloma patient population by risk, SCT eligibility, and R-ISS stages.

Additional Details

Publisher : Global Data

Reference : GDHCER200-19

Number of Pages : 42

Report Format : PDF

Publisher Information :



GlobalData »

BioPortfolio
Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data

**Best Prices
Guaranteed**

bioportfolio.co.uk

Table Of Contents for Multiple Myeloma: Epidemiology Forecast to 2027 [Published by Global Data]

- 1 Table of Contents1.1 List of Tables1.2 List of Figures2 Multiple Myeloma: Executive Summary2.1 Related Reports2.2 Upcoming Reports3 Epidemiology3.1 Disease Background3.2 Risk Factors and Comorbidities3.3 Global and Historical Trends3.3.1 Diagnosed Incidence of MM3.4 Forecast Methodology3.4.1 Sources3.4.2 Forecast Assumptions and Methods3.4.3 Diagnosed Incident Cases of MM3.4.4 Diagnosed Incident Cases of MM by Symptom Status3.4.5 Diagnosed Incident Cases of MM by SCT Eligibility3.4.6 Diagnosed Incident Cases of MM by Chromosomal Abnormalities3.4.7 Diagnosed Incident Cases of MM by R-ISS Staging3.4.8 Diagnosed Prevalent Cases of MM3.5 Epidemiological Forecast for Multiple Myeloma (2017-2027)3.5.1 Diagnosed Incident Cases of MM3.5.2 Age-Specific Diagnosed Incident Cases of MM3.5.3 Sex-Specific Diagnosed Incident Cases of MM3.5.4 Diagnosed Incident Cases of MM by Symptom Status3.5.5 Diagnosed Incident Cases of MM by SCT Eligibility3.5.6 Diagnosed Incident Cases of MM by Chromosomal Abnormalities3.5.7 Diagnosed Incident Cases of MM by R-ISS Staging3.5.8 Diagnosed Prevalent Cases of MM3.6 Discussion3.6.1 Epidemiological Forecast Insight3.6.2 Limitations of Analysis3.6.3 Strengths of Analysis4 Appendix4.1 Bibliography4.2 About the Authors4.2.1 Epidemiologist4.2.2 Reviewers4.2.3 Global Director of Therapy Analysis and Epidemiology4.2.4 Global Head and EVP of Healthcare Operations and Strategy4.3 About GlobalData4.4 Contact Us4.5 Disclaimer

List Of Tables in Multiple Myeloma: Epidemiology Forecast to 2027 [Published by Global Data]

1.1 List of Tables

Table 1: Risk Factors for MM

List Of Figures, Charts and Diagrams in Multiple Myeloma: Epidemiology Forecast to 2027 [Published by Global Data]

1.2 List of Figures

Figure 1: 8MM, Diagnosed Incident Cases of MM, Both Sexes, Ages ≥ 40 Years, 2017 and 2027

Figure 2: 8MM, Diagnosed Prevalent Cases of MM, Both Sexes, Ages ≥ 40 Years, 2017 and 2027

Figure 3: 8MM, Age-Standardized Diagnosed Incidence of MM (Cases per 100,000 Population), Men, Ages ≥ 40 Years, 2007 to 2027

Figure 4: 8MM, Age-Standardized Diagnosed Incidence of MM (Cases per 100,000 Population), Women, Ages ≥ 40 Years, 2007 to 2027

Figure 5: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of MM

Figure 6: 8MM, Sources Used to Forecast the Diagnosed Prevalent Cases of MM

Figure 7: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of MM by Symptom Status

Figure 8: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of MM by SCT Eligibility

Figure 9: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of MM by Chromosomal Abnormalities

Figure 10: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of MM by R-ISS Staging

Figure 11: 8MM, Diagnosed Incident Cases of MM, Both Sexes, Ages ≥ 40 Years, N, 2017

Figure 12: 8MM, Age-Specific Diagnosed Incident Cases of MM, Both Sexes, Ages ≥ 40 Years, N, 2017

Figure 13: 8MM, Sex-Specific Diagnosed Incident Cases of MM, Ages ≥ 40 Years, N, 2017

Figure 14: 8MM, Diagnosed Incident Cases of MM by Symptom Status, Both Sexes, Ages ≥ 40 Years, N, 2017

Figure 15: 8MM, Diagnosed Incident Cases of MM by SCT Eligibility, Both Sexes, Ages ≥ 40 Years, N, 2017

Figure 16: 8MM, Diagnosed Incident Cases of MM by Chromosomal Abnormalities, Both Sexes, Ages ≥ 40 Years, N, 2017

Figure 17: 8MM, Diagnosed Incident Cases of MM by R-ISS Staging, Both Sexes, Ages ≥ 40 Years, N, 2017

Figure 18: 8MM, Diagnosed Prevalent Cases of MM, Both Sexes, Ages ≥ 40 Years, N, 2017

How to Buy...

Multiple Myeloma: Epidemiology Forecast to 2027 [Published by Global Data]

Option 1 - Online

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/230880>

Option 2 - Request a Proforma Invoice

Fill in the details below, and either **Scan** this page **and email** it to us at pdb@bioportfolio.co.uk or **Fax** it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

Your Name:

Job Title:

Your Email:

Your Contact Phone:

Company Name:

Address:

Post/Zip Code:

Country:

P.O. Number:

Any Other Instructions:

Pricing Options: (please tick one)

- \$3995** | Single User Price
- \$7990** | Site License Price
- \$11985** | Global License Price

Payment Options: (please tick one)

- Online Credit Card** (we will email you the invoice with a payment link)
- Direct Wire Transfer** (we will email you the invoice with our bank details)

Authorising Signature:

Option 3 - Phone Us on +44 (0)7887 945155

We will be delighted to give you our personal attention.